The system is said to offer continuous imaging during treatment, allowing clinicians to see where the radiation dose is being delivered and adapt to changes and movement in the patient’s anatomy in real-time.

According to ViewRay, MRIdian tracks soft-tissues of the tumor directly in fast planar images, and compares the target to the plan and only allows treatment when the target is in range.

ViewRay president and CEO Chris Raanes said: "Being granted CE Mark opens the door for us to deliver the world’s only clinical MRI-guided radiation therapy platform to hundreds of medical facilities.

"With this milestone, we look forward to making MRI-guided radiation therapy a globally accessible treatment option for cancer patients."

The system will avoid X-ray exposure that is inherent in CT scans, in addition to improving soft-tissue visualization. The MRIdian system obtained 510(k) approval from the US Food and Drug Administration in May 2012.